Treatment patterns for relapsed and refractory Hodgkin lymphoma in a community oncology setting

Abstract

There is little data about treatment practices for relapsed/refractory Hodgkin Lymphoma (HL) in nonacademic settings. We describe sequential treatments and outcomes among HL patients who experienced treatment failure in an integrated community-oncology setting. We performed a retrospective cohort study among patients ≥12 years diagnosed with Stage II–IV HL from 2007 to 2012 at Kaiser Permanente Southern California (KPSC). Of 463 HL patients, 75 (16.1%) experienced treatment failure. Patients with failure received between 1 and 8 salvage therapies; 28% received ≥4 lines of therapy. Fifty-nine of 75 (79%) were initially salvaged with ifosfamide-based therapy, 44 of whom underwent hematopoietic cell transplant. Ultimately, 47% of patients died, with most deaths due to HL. Survival was shorter with increasing age at diagnosis (p = 0.02) and with greater number of lines of therapy (p = 0.02). In a community oncology setting, HL patients received multiple lines of salvage. Despite extensive treatment, nearly half of patients died of HL following relapsed/refractory disease.

Keywords:

• Hodgkin Lymphoma
• chemotherapy
• survival

Disclosure statement

AJK: none; CC: none; AMR: none, AE: Research to Practice (Honoraria); Seattle Genetics (consultancy & honoraria); Pharmacyclics (Honoraria & DMC); Verastem (consultancy & honoraria); Bayer (consultancy & honoraria); Affimed (consultancy & honoraria); Takeda (research funding), Merck (research funding); HC: none; LX: none, SKP: Seattle Genetics (consultancy). No potential conflict of interest was reported by the author(s).

Data availability statement

The data are not available for sharing.

Additional information

Funding

This research was funded in part by a grant from Seattle Genetics. AJK is supported by a career development award from the Lymphoma Research Foundtion.